CN102245609B - 可用作激酶抑制剂的咪唑并哒嗪甲腈 - Google Patents

可用作激酶抑制剂的咪唑并哒嗪甲腈 Download PDF

Info

Publication number
CN102245609B
CN102245609B CN200980149133.2A CN200980149133A CN102245609B CN 102245609 B CN102245609 B CN 102245609B CN 200980149133 A CN200980149133 A CN 200980149133A CN 102245609 B CN102245609 B CN 102245609B
Authority
CN
China
Prior art keywords
substituted
occurrence
alkyl
independently selected
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980149133.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102245609A (zh
Inventor
布赖恩.芬克
陈利冰
阿什维尼库马.加韦
何立崎
金崇薰
安德鲁.内蒂昂
赵玉芬
张丽台
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102245609A publication Critical patent/CN102245609A/zh
Application granted granted Critical
Publication of CN102245609B publication Critical patent/CN102245609B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mobile Radio Communication Systems (AREA)
CN200980149133.2A 2008-10-09 2009-10-08 可用作激酶抑制剂的咪唑并哒嗪甲腈 Expired - Fee Related CN102245609B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
US61/104,045 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN102245609A CN102245609A (zh) 2011-11-16
CN102245609B true CN102245609B (zh) 2016-03-09

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980149133.2A Expired - Fee Related CN102245609B (zh) 2008-10-09 2009-10-08 可用作激酶抑制剂的咪唑并哒嗪甲腈

Country Status (27)

Country Link
US (3) US8252795B2 (enExample)
EP (1) EP2350081B1 (enExample)
JP (1) JP5560278B2 (enExample)
KR (1) KR20110075010A (enExample)
CN (1) CN102245609B (enExample)
AR (1) AR073818A1 (enExample)
AU (1) AU2009302360B2 (enExample)
BR (1) BRPI0920135A2 (enExample)
CA (1) CA2739782A1 (enExample)
CL (1) CL2011000777A1 (enExample)
CO (1) CO6361936A2 (enExample)
CY (1) CY1114539T1 (enExample)
DK (1) DK2350081T3 (enExample)
EA (1) EA018163B1 (enExample)
ES (1) ES2426951T3 (enExample)
HR (1) HRP20130787T1 (enExample)
IL (1) IL211693A (enExample)
MX (1) MX2011003304A (enExample)
NZ (1) NZ591712A (enExample)
PE (1) PE20110411A1 (enExample)
PL (1) PL2350081T3 (enExample)
PT (1) PT2350081E (enExample)
SI (1) SI2350081T1 (enExample)
SM (1) SMT201300109B (enExample)
TW (1) TWI491610B (enExample)
WO (1) WO2010042699A1 (enExample)
ZA (1) ZA201102423B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
CA2914745A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CA3028727A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals, Inc. Ck2 inhibitors, compositions and methods thereof
PL3498693T3 (pl) * 2016-08-10 2025-03-24 Takeda Pharmaceutical Company Limited Związek heterocykliczny
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
BR112020013313B1 (pt) 2017-12-29 2023-10-31 Jiangsu Flag Chemical Industry Co., Ltd Composto de pirazolamida de fórmula geral i, composto de fórmula ii, método para preparar um composto de fórmula geral i, uso do composto de fórmula geral i, composição inseticida e método para controlar pragas
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
AU2019212969B2 (en) * 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
KR102865925B1 (ko) * 2019-03-05 2025-09-26 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
KR102915019B1 (ko) 2019-04-24 2026-01-21 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
AU2022216415A1 (en) * 2021-02-03 2023-09-21 Sanofi DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
AU2023212957A1 (en) * 2022-01-25 2024-08-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
WO2024039767A1 (en) * 2022-08-18 2024-02-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases
CN115947756B (zh) * 2022-12-13 2025-08-01 西湖大学 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
US20080045536A1 (en) * 2005-09-22 2008-02-21 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
WO2008016192A3 (en) * 2006-08-04 2008-05-08 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2551867C (en) * 2003-12-31 2010-08-17 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
US20080045536A1 (en) * 2005-09-22 2008-02-21 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016192A3 (en) * 2006-08-04 2008-05-08 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Asymmetric expression of protein kinase CK2 subunits in human kidney tumors;Stalter et al;《Biochem. Biophys. Res. Commun.》;19940715;第202卷(第1期);141-147 *
Protein kinase CK2 in mammary gland tumorigenesis;Landesman-Bollag et al;《Oncology》;20011231;3247-3257 *
蛋白激酶CK2在喉正常组织、喉癌前病变和喉癌中的表达及意义;吴蕾;《中国优秀硕士学位论文全文数据库 》;20090303;1-38 *
蛋白激酶CK2抑制剂的筛选;李春梅 等;《中国药理通讯》;20031231;第20卷(第3期);25-26 *

Also Published As

Publication number Publication date
CY1114539T1 (el) 2016-10-05
EA201100580A1 (ru) 2011-10-31
EP2350081A1 (en) 2011-08-03
IL211693A0 (en) 2011-06-30
CA2739782A1 (en) 2010-04-15
US9371328B2 (en) 2016-06-21
NZ591712A (en) 2012-10-26
US8252795B2 (en) 2012-08-28
HRP20130787T1 (en) 2013-09-30
WO2010042699A1 (en) 2010-04-15
AU2009302360B2 (en) 2014-12-11
PE20110411A1 (es) 2011-06-22
IL211693A (en) 2015-06-30
CO6361936A2 (es) 2012-01-20
HK1154002A1 (en) 2012-04-13
DK2350081T3 (da) 2013-10-14
BRPI0920135A2 (pt) 2019-09-24
US20100113458A1 (en) 2010-05-06
PL2350081T3 (pl) 2013-10-31
EA018163B1 (ru) 2013-05-30
AU2009302360A1 (en) 2010-04-15
TW201018686A (en) 2010-05-16
SMT201300109B (it) 2013-11-08
AR073818A1 (es) 2010-12-01
SI2350081T1 (sl) 2013-11-29
ZA201102423B (en) 2012-09-26
ES2426951T3 (es) 2013-10-25
MX2011003304A (es) 2011-04-21
US20140179674A1 (en) 2014-06-26
PT2350081E (pt) 2013-09-24
US20120283241A1 (en) 2012-11-08
JP5560278B2 (ja) 2014-07-23
CL2011000777A1 (es) 2011-08-12
EP2350081B1 (en) 2013-07-03
TWI491610B (zh) 2015-07-11
CN102245609A (zh) 2011-11-16
KR20110075010A (ko) 2011-07-05
JP2012505235A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
TWI491610B (zh) 作為激酶抑制劑之咪唑并嗒腈
CN101594871B (zh) 吡咯并嘧啶化合物及其用途
US8791257B2 (en) Substituted pyrrolotriazines as protein kinase inhibitors
CN105916857B (zh) 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途
CN101981033B (zh) 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN102325752B (zh) 咔唑和咔啉激酶抑制剂
CN105102453B (zh) 作为布罗莫结构域抑制剂的苯并咪唑酮衍生物
EP2344504B1 (en) Pyrrolotriazine kinase inhibitors
CN102471339A (zh) 激酶的吡咯并吡啶抑制剂
WO2023030295A1 (zh) 泛素特异性蛋白酶1(usp1)抑制剂
CN102482278A (zh) 作为pi3k抑制剂的嘧啶酮类
EP3141552A1 (en) Thienopyrimidine derivatives having inhibitory activity for protein kinase
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN109575022A (zh) 一种化合物及其用途
RU2415853C2 (ru) Бензимидазолы, применимые в качестве ингибиторов протеинкиназ
CN115515934A (zh) Nampt调节剂
KR20140023269A (ko) 치환된 메틸아민, 세로토닌 5-ht6 수용체의 길항제, 이의 제조방법 및 이의 용도
HK1154002B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160309

Termination date: 20181008

CF01 Termination of patent right due to non-payment of annual fee